Clinical

Dataset Information

0

Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI

ABSTRACT: Primary objectives: Progression free survival

DISEASE(S): Metastatic Colorectal Cancer,Carcinoma Del Colon-retto Inoperabile E Metastatico,Unresectable And Metastatic Colorectal Cancer

PROVIDER: 2532389 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
| S-EPMC3500363 | biostudies-literature
Unknown Randomized phase II study of TX followed by XELOX versus the reverse sequence for chemo-naive patients with metastatic gastric cancer.
| S-EPMC9643736 | biostudies-literature
Unknown Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
| S-EPMC3528380 | biostudies-literature
Clinical Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
| 2061270 | ecrin-mdr-crc
Unknown A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
| S-EPMC3399650 | biostudies-literature
Unknown Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study).
| S-EPMC8161763 | biostudies-literature
Unknown FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
| S-EPMC7533956 | biostudies-literature
Unknown A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
| S-EPMC6342906 | biostudies-literature
Unknown Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer.
| S-EPMC11647033 | biostudies-literature
Unknown Efficacy of Postoperative FOLFOX <i>Versus</i> XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet-Lymphocyte Ratio in Patients Receiving XELOX.
| S-EPMC7786002 | biostudies-literature